Proteinqure

Proteinqure company information, Employees & Contact Information

Updated May 2026

Quick answer

Proteinqure is a Biotechnology Research company and founded in 2017. It has approximately 34 employees on record. Contact data was last refreshed in May 2026. Find Proteinqure's verified employee emails, phone numbers, headquarters address, and key decision makers below.

Explore related pages

Related company profiles:

ProteinQure is a biotech company focused on the design of novel exotic peptides with broad therapeutic applications. Powered by atomic-level simulations and artificial intelligence, we design dynamic peptides that take drugs straight to their target – outperforming other treatment delivery systems. By daring to deliver therapeutics in a novel way we are changing the game for drug development and bringing hope to patients with previously untreatable diseases. At ProteinQure, we pride ourselves on our unique, diverse and cross-disciplinary team that brings together experts from experimental & computational biology, machine learning and software engineering.

Company Details

Employees
34
Founded
-
Address
119 Spadina Ave, 304,canada
Phone
+1 (437) 779 8504
Email
te****@****ure.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
Keywords
Associate jobs.
HQ
Toronto, Ontario
Looking for a particular Proteinqure employee's phone or email?

Proteinqure Questions

News

ProteinQure Receives Regulatory Clearance to Initiate Phase I Trial for PQ203 in the U.S. and Canada; Granted FDA Fast Track Designation - Business Wire

ProteinQure Receives Regulatory Clearance to Initiate Phase I Trial for PQ203 in the U.S. and Canada; Granted FDA Fast Track Designation Business Wire

PQ203 Receives Regulatory Clearance for Breast Cancer Trial - Targeted Oncology

PQ203 Receives Regulatory Clearance for Breast Cancer Trial Targeted Oncology

ProteinQure Announces First Patient Dosed in Phase I Clinical Trial of PQ203 in Advanced Metastatic Cancer - The AI Journal

ProteinQure Announces First Patient Dosed in Phase I Clinical Trial of PQ203 in Advanced Metastatic Cancer The AI Journal

ProteinQure Closes $11M in Series A Financing - FinSMEs

ProteinQure Closes $11M in Series A Financing FinSMEs

ProteinQure to Present Data on PQ203, a Novel Peptide-Drug Conjugate for Triple Negative Breast Cancer, at 2024 San Antonio Breast Cancer Symposium - Yahoo Finance

ProteinQure to Present Data on PQ203, a Novel Peptide-Drug Conjugate for Triple Negative Breast Cancer, at 2024 San Antonio Breast Cancer Symposium Yahoo Finance

ProteinQure nabs $11M to bring AI-designed peptide-drug conjugate to the clinic - FirstWord Pharma

ProteinQure nabs $11M to bring AI-designed peptide-drug conjugate to the clinic FirstWord Pharma

Proteinqure’s PQ-203 cleared to enter clinic in US and Canada - BioWorld MedTech

Proteinqure’s PQ-203 cleared to enter clinic in US and Canada BioWorld MedTech

Medtech AI startups ProteinQure and AssistIQ each close Series A rounds - BetaKit

Medtech AI startups ProteinQure and AssistIQ each close Series A rounds BetaKit

ProteinQure Raises Series A Financing to Advance First AI-Designed Peptide Therapeutic into Clinical Trials - BioSpace

ProteinQure Raises Series A Financing to Advance First AI-Designed Peptide Therapeutic into Clinical Trials BioSpace

ProteinQure Collaborates with AstraZeneca to Design Novel Peptide Therapeutics - Business Wire

ProteinQure Collaborates with AstraZeneca to Design Novel Peptide Therapeutics Business Wire

ProteinQure raises $5.2 million CAD for protein-focused drug design platform - BetaKit

ProteinQure raises $5.2 million CAD for protein-focused drug design platform BetaKit

Top Proteinqure Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant